Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly and Company is offering multiple series of unsecured, unsubordinated debt securities (floating rate and fixed rate notes) pursuant to a preliminary prospectus supplement. The company intends to use net proceeds for general corporate purposes, including repayment of commercial paper and potentially to fund all or a portion of the upfront cash consideration for its pending Centessa and Kelonia acquisitions. Certain series (the “Centessa Mandatorily Redeemable Notes”) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by five business days after the later of March 31, 2027 (or any agreed Outside Date); those notes would be redeemable at 101% of principal plus accrued interest. The floating rate notes reference Compounded SOFR (with related Benchmark Transition provisions). Notes will be issued in minimum denominations of $2,000 and delivered in book-entry form through DTC, Clearstream and Euroclear.
Eli Lilly & Co reported a Schedule 13G ownership disclosure showing Vanguard Capital Management beneficially owns 61,295,605 shares of Common Stock, representing 6.48% of the class. The filing states Vanguard has sole dispositive power over 61,295,605 shares and sole voting power over 7,933,831 shares. The disclosure names affiliated Vanguard entities and notes holdings include securities held for Vanguard funds and managed accounts. The signature date is 05/01/2026.
Eli Lilly posted very strong Q1 2026 results, with revenue of $19.8 billion, up 56% from a year earlier, and diluted EPS of $8.26 versus $3.06. Net income rose to $7.4 billion, a 168% increase.
Growth was driven by incretin medicines. Mounjaro generated $8.7 billion in revenue and Zepbound $4.2 billion, and together with other cardiometabolic drugs they made up 65% of total revenue. International sales nearly doubled, helped by Mounjaro launches, though prices fell in some markets such as China.
Research and development spending increased 28% to $3.5 billion as Lilly advanced an extensive late-stage pipeline, while acquired in-process R&D charges dropped sharply. Operating cash flow reached $5.3 billion, funding heavy capital investment, the $1.1 billion Ventyx acquisition, $2.3 billion of share repurchases, and $1.5 billion in dividends. Management highlights rising pricing and reimbursement pressure, including U.S. drug pricing reforms and new agreements that lower certain prices, as key risks alongside the company’s growing reliance on incretin therapies.
Eli Lilly (LLY) reported very strong first-quarter 2026 results and raised its full-year outlook. Q1 2026 revenue rose 56% to $19.8 billion, driven by a 65% increase in volume, partially offset by lower realized prices, especially for Mounjaro and Zepbound. Reported EPS increased 170% to $8.26, while non-GAAP EPS rose 156% to $8.55, helped by lower acquired IPR&D charges versus last year.
Key obesity and diabetes medicines continued to power growth: Mounjaro revenue jumped 125% to $8.7 billion, and Zepbound revenue grew 80% to $4.2 billion. Lilly also reported rapid growth across newer immunology, oncology, and neuroscience products. U.S. revenue grew 43% to $12.1 billion, while revenue outside the U.S. rose 81% to $7.7 billion.
The company raised 2026 guidance, now expecting full-year revenue of $82–$85 billion and non-GAAP EPS of $35.50–$37.00. Gross margin stayed above 80% on both a reported and non-GAAP basis, even as the company increased spending on research, development, and launches. Lilly highlighted the U.S. FDA approval and launch of Foundayo, its once-daily oral GLP-1 pill for weight loss, plus multiple positive Phase 3 results and several announced acquisitions to expand its pipeline.
Eli Lilly & Co director Gabrielle Sulzberger received a compensation-related stock grant rather than buying shares on the market. On this award, she acquired 5.39 shares of common stock at $919.90 per share, bringing her direct holdings to 2,981.599 shares.
According to the disclosure, she elected to defer this grant into stock units under the Lilly Directors' Deferral Plan. These units will be settled in Eli Lilly common stock after she separates from board service, turning current cash compensation into future share-based value.
ELI LILLY & Co director Juan R. Luciano received a small stock grant. He acquired 17.3030 shares of common stock as a grant or award at a reported price of $919.9000 per share. After this transaction, he directly holds a total of 16,834.7230 Eli Lilly common shares.
ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade. He acquired 10.78 shares of common stock at $919.90 per share through a grant classified as a “grant, award, or other acquisition.”
According to the footnote, he elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, his direct holdings total 75,269.556 Lilly common shares.
ELI LILLY & Co director Ralph Alvarez increased his equity-based compensation exposure through a deferred stock award. He acquired 13.498 shares of common stock equivalent as a grant or award at $919.90 per share, electing to defer cash compensation into stock units under the Lilly Directors' Deferral Plan.
After this award, his directly held common stock totaled 55,614.713 shares, with an additional 758 shares held indirectly by a trust. The deferred stock units will be settled in shares of common stock following his separation from service, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
Lilly Endowment, Inc. reports beneficial ownership of 91,896,978 shares of Eli Lilly and Company common stock, representing 9.7% of the class as of March 31, 2026.
The filing states the 9.7% figure is based on 944,818,881 shares outstanding as of February 25, 2026, and the statement is signed April 20, 2026.